Compare First Trust NASDAQ 100 Technology Index Fund (QTEC) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
First Trust NASDAQ 100 Technology Index Fund vs Travere Therapeutics Inc. Common Stock — how do they compare? First Trust NASDAQ 100 Technology Index Fund trades at $303.09 (market cap $4.40B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B). The key difference: First Trust NASDAQ 100 Technology Index Fund and Travere Therapeutics Inc. Common Stock are close in size by market cap, and First Trust NASDAQ 100 Technology Index Fund is more actively traded (160,706 versus 1,668,577). Which is the better fit depends on your goals — on Pluang, investors hold First Trust NASDAQ 100 Technology Index Fund for 40 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| QTEC | TVTX | |
|---|---|---|
Market Cap | $4.40B | $4.88B |
Volume | 160,706 | 1,668,577 |
Sector | Broad Market / Factor | Health |
52-Week High | $340.28 | $67.52 |
52-Week Low | $207.03 | $26.79 |
Typical Hold Time | 40 Days | 0 Days |
Enterprise Value | — | $5.01B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
QTEC, the First Trust NASDAQ-100-Technology Sector ETF, trades at $324.27, down 0.59% on the day. The technical outlook is bullish based on moving averages, with key support at $321 and resistance at $335. Recent analysis highlights its equal-weighted exposure to the technology sector and better liquidity compared to peers.
The ETF offers broad tech exposure but faces sector-specific volatility risks. Upside potential hinges on technology sector performance, while downside risks include macroeconomic pressures on growth stocks. Investor sentiment remains mixed with a neutral oscillator reading.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About First Trust NASDAQ 100 Technology Index Fund
QTEC is an ETF that seeks to track the performance of the NASDAQ-100 Technology Sector Index. The fund provides targeted exposure to companies within the NASDAQ-100 that are classified as technology or telecommunications companies, focusing on firms involved in software, hardware, and related services. QTEC is a tool for investors seeking focused exposure to high-growth, large-cap technology companies listed on the NASDAQ exchange.
Read more on QTEC →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
